Growth Hormone Axis · GHRP · Compounded 503A
Hexarelin: a potent GH secretagogue with cardiac signaling.
Hexarelin is a synthetic 6-amino-acid growth hormone-releasing peptide (GHRP) — a close relative of GHRP-6 with greater potency. It strongly stimulates pituitary GH release through the ghrelin / GHS receptor and has been studied for a unique direct effect on the heart through a distinct receptor (CD36).
Free shipping over $150 · Pay with card or crypto
What Hexarelin is
Hexarelin (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide GHRP developed in the 1990s. It is one of the most potent GHRPs studied — known for strong, fast pituitary GH release.
In addition to GH release through GHS-R1a, hexarelin binds the scavenger receptor CD36 in cardiac tissue — a feature not shared by all GHRPs and the basis for a body of cardioprotective research.
It is investigational in the U.S. It is not FDA-approved. Compounded forms are dispensed by licensed 503A pharmacies under physician prescription.
How it works
Hexarelin activates GHS-R1a on pituitary somatotrophs, triggering a pulse of GH release. The pulse is large and rapid — bigger than ipamorelin or GHRP-2 at comparable doses.
It also activates the hypothalamic GH-releasing pathway and may indirectly stimulate ACTH and prolactin at higher doses — a key reason kindr selectively considers it.
Independent of GH release, hexarelin binds cardiac CD36 and produces a cytoprotective signal in animal models of ischemia and dilated cardiomyopathy.
What patients use it for
Strong GH pulse
Among the most potent GHRPs for stimulating endogenous GH release.
Cardiac research signal
Animal and small clinical studies show a direct cardioprotective effect through CD36, distinct from GH.
Recovery and body composition
GH pulse supports the same downstream recovery, sleep, and lean-mass effects seen across the GHRP class.
Evidence summary
Imbimbo BP et al. (Eur J Clin Invest, 1994) — original human GH-release pharmacology.
Locatelli V, Torsello A. Hexarelin and growth hormone secretagogues: cardiac effects. Pharmacol Res (2004).
Long-term human outcome trials are limited; the cardiac literature is largely preclinical.
Dosing and clinical context
General clinical context only. Kindr Health physicians determine the appropriate dose and protocol for each patient based on history and labs. This is not a prescription or dosing recommendation.
No FDA-approved human dosing exists. Compounded protocols typically use low-microgram subcutaneous dosing 1–3 times per day.
Receptor desensitization is meaningful with extended daily use — limited cycles are typical.
A kindr physician determines whether a trial is appropriate and pairs it with appropriate labs (IGF-1, prolactin, cortisol).
Safety and contraindications
Higher-dose hexarelin can transiently raise cortisol and prolactin — periodic labs are part of supervision.
GH-pathway therapies require pre-treatment IGF-1 and active-cancer screening.
Receptor desensitization with chronic daily use — cycled protocols.
Not for use in pregnancy, breastfeeding, or active malignancy.
Who it's typically considered for
- Adults pursuing a physician-supervised GH-axis protocol who tolerate the GHRP class
- Patients with clean cancer screening and normal-to-low IGF-1
- Patients who would benefit from a stronger GH pulse than ipamorelin provides
Frequently asked questions
Hexarelin vs ipamorelin?
Ipamorelin is selective — clean GH pulse with minimal cortisol or prolactin rise. Hexarelin produces a larger GH pulse but can raise cortisol/prolactin at higher doses.
Hexarelin vs GHRP-6?
Hexarelin is more potent on a per-dose basis and is less hunger-inducing than GHRP-6. Both target the same receptor.
Is it FDA-approved?
No. U.S. use is investigational and compounded.
Why pair with a GHRH?
Pairing a GHRP (like hexarelin) with a GHRH (like CJC-1295 or sermorelin) produces a synergistic GH pulse greater than either alone.
Is it safe long-term?
Receptor desensitization and prolactin/cortisol effects favor short cycled protocols under supervision rather than indefinite daily use.
Sources
- Imbimbo BP et al. Growth hormone (GH)-releasing activity of hexarelin in humans. Eur J Clin Invest (1994). — pubmed.ncbi.nlm.nih.gov/7995061
- Locatelli V, Torsello A. Hexarelin: a growth hormone secretagogue with cardiotropic activity. Pharmacol Res (2004). — pubmed.ncbi.nlm.nih.gov/15275938
- Broglio F et al. The endocrine response to ghrelin and synthetic growth hormone secretagogues in normal humans. J Clin Endocrinol Metab (2003). — pubmed.ncbi.nlm.nih.gov/12727996
Considering Hexarelin?
A Kindr Health physician reviews every longevity intake — peptides are prescribed only when medically indicated based on your history and labs. There is no charge for the initial review.
Related peptides
Medically reviewed by Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team (physician-supervised)
NPI 1609792902 · Last reviewed: July 3, 2026
Last reviewed July 3, 2026. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products. Prescriptions require a clinical evaluation; a Kindr Health physician determines eligibility. Not for use in pregnancy. This page provides educational information and is not medical advice.